Clinical Trials Logo

Clinical Trial Summary

To analyse the impact on cycle outcome of LH supplementation in ovarian stimulation controlled with a GnRH antagonist in two ages groups: patients upto 35 years old, and patients aged between 36 and 39 years old.


Clinical Trial Description

All patients received an oral contraceptive pill with 0.030 mg of ethinyl-estradiol and 3.0 mg of drospirenone the cycle prior to ovarian stimulation. On the second day of menstruation, patients started ovarian stimulation as follows:

Patients < 36: 225 IU/day of recombinant FSH (FSH alone group) or 150 IU of rFSH and 75 IU of rLH/day (FSH+LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist Cetrorelix is added until the day of rCG administration.

Patients 36-39: Initial dose of 300 IU of rFSH /day (FSH alone group)) or 225 IU of rFSH and 75 IU of rLH/day (FSH + LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist Cetrorelix is added until the day of rCG administration.

A maximum of 3 embryos were transferred on day 3 of embryo development. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01037699
Study type Interventional
Source Instituto Valenciano de Infertilidad, IVI VALENCIA
Contact
Status Completed
Phase Phase 3
Start date January 2005
Completion date March 2008

See also
  Status Clinical Trial Phase
Completed NCT01121991 - A Prospective Study to Evaluate the Addition of Subcutaneous Recombinant Human-Luteinizing Hormone With Recombinant Human-Follicle Stimulating Hormone on Follicular Development in Women Undergoing Ovarian Stimulation for Assisted Reproductive Technologies Phase 3
Not yet recruiting NCT04539067 - Effect of Controlled Ovarian Stimulation in Quality of Oocyte and Embryo Phase 2
Recruiting NCT02715336 - Efficacy and Safety of Medication Used to Stimulate Ovulation Phase 4
Not yet recruiting NCT03298750 - Mechanical Stimulation of the Ovary for Infertility Treatment in Patients With Very Low Ovarian Reserve N/A
Completed NCT03939403 - Conventional Ovarian Stimulation vs. Single Injection Stimulation of Corifollitropin Alfa in Oocyte Donor Phase 4
Recruiting NCT06142708 - The Effect of Dual Trigger (GnRH Agonist + hCG) for Final Maturation in Oocyte Donors With History of a Previous Cycle With Suboptimal Response to GnRH Agonist Only Trigger N/A
Recruiting NCT05166668 - Letrozole /GnRH Antagonist Protocol in Women Over 40 Years Undergoing ICSI Cycle N/A
Completed NCT04549649 - The Effect of Dual Trigger for Final Oocyte Maturation on IVF/ICSI Outcomes in Patients With Suboptimal Ovarian Response N/A
Terminated NCT01816789 - Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles Phase 4
Completed NCT00823004 - Antagonist/Letrozole in Poor Responders Phase 1/Phase 2
Not yet recruiting NCT06175832 - PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study Phase 4
Completed NCT01145144 - Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment N/A
Completed NCT00830492 - Clomiphene Citrate (CC)/Gonadotropin/Gonadotropin Releasing Hormone (GnRH) Antagonist Versus Gonadotropin/GnRH Agonist Phase 4
Completed NCT00829075 - Impact of Three Different Gonadotrophin Regimes on Egg Donation Program Phase 4
Completed NCT01112358 - Lutropin Alfa in Women at Risk of Poor Response Phase 2
Recruiting NCT03400722 - Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response Phase 4
Completed NCT00669786 - Human Menopausal Gonadotropin (HMG) vs Recombinant Follicle Stimulating Hormone (rFSH) in Gonadotropin Releasing Hormone (GnRH) Antagonist Cycles Phase 3